Linda Neuman

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Linda Neuman

Spyre Therapeutics, Inc. reported in an 8-K filed April 12, 2023 that Linda Neuman resigned as Chief Medical Officer, effective April 14, 2023.

“Michael Hanley, the Company's Chief Business Officer, and Linda Neuman, the Company's Chief Medical Officer, will be departing from the Company, effective April 14, 2023.”

Spyre Therapeutics, Inc. Form 8-K, filed April 12, 2023 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Research with Equibles

Turn this profile into a cited research brief

Start with a question tailored to the filings and events on this page, or connect Equibles financial data to ChatGPT or Claude.

Suggested question: “Summarize Linda Neuman's recent executive appointments or departures and cite the source filings.”

Use in your AI

Affiliation history

Recorded current and former roles; source labels appear when available.

Spyre Therapeutics, Inc. (SYRE)
Proxy statement

Start not stated–2023-04-17

Last confirmed by a filing; no departure on record
Spyre Therapeutics, Inc. (SYRE)
Proxy statement

Start not stated–2023-04-14

Company network

Recorded roles and call appearances connecting this person to public companies.

Spyre Therapeutics, Inc.

SYRE

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.

Executive change Resigned: Chief Medical Officer Spyre Therapeutics, Inc. (SYRE)
2023-04-14